Results 91 to 100 of about 6,725 (159)

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models. [PDF]

J Clin Pharmacol
Gaffney A, Franchetti Y, Desrosiers M, Trame MN, Jewell RC.   +4 more
europepmc   +1 more source

Poly(ADP-ribose) polymerase inhibitor maintenance therapy in ovarian cancer: a single-center retrospective study. [PDF]

Front Oncol
Pence S, Dyson K, Waters K, Elliott JO, Rath K, Pierce S, Harper A, Calo C, Clements AE.   +8 more
europepmc   +1 more source

Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice. [PDF]

Br J Cancer
Macdonald CJ, McWhirter A, Vaidyanathan A, Ferguson MJ, Eberl HC, Stronach EA, Sawers L, Smith G.   +7 more
europepmc   +1 more source

The evolving role of immunotherapy in ovarian cancer. [PDF]

Cancer
Veneziani AC, Venegas L, Oza AM.
europepmc   +1 more source

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. [PDF]

Signal Transduct Target Ther
Camps-Fajol C, Minguillón J, Surrallés J.   +2 more
europepmc   +1 more source

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data. [PDF]

Oncol Res
Gasperoni L, Del Bono L, Farolfi A, Messori A, Damuzzo V.   +4 more
europepmc   +1 more source

Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System). [PDF]

Curr Oncol
Ahmed Z, Sayyid R, Yazdanpanah O, Samaeekia R, Kalebasty AR, Lee DI, Shahait M.   +6 more
europepmc   +1 more source